FDA lifts clinical hold on NeuroDerm’s ND0612 for Parkinson’s

Monday, May 11, 2015

The FDA has lifted the clinical hold on U.S. clinical studies of ND0612H and ND0612L, primary product candidates based on proprietary, subcutaneously-delivered Levodopa/Carbidopa (LD/CD) liquid formulation for the treatment of Parkinson’s disease, owned by NeuroDerm, a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases. The hold was lifted after the FDA reviewed additional information related to the product candidates’ delivery devices. U.S. clinical development of these product candidates is therefore cleared to proceed in the second half of 2015.

[Read More]

Michael J. Fox Foundation announces research partners

Friday, July 12, 2013

Research projects from five biopharmaceutical companies in the U.S., Canada and Israel comprise the 2013 first half of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Partnering Program. Participants’ research projects are presented directly to industry groups that may wish to invest in further development. By connecting industry leaders with those studies ripe for investment, the Foundation aims to drive forward promising research in Parkinson’s disease (PD) through the pipeline of drug development and eventually into patients’ hands.

[Read More]

NeuroDerm’s Parkinson’s trial meets primary endpoints

Wednesday, November 9, 2011

NeuroDerm has reported the results of a phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet-CR, Sinemet or Stalevo, in patients with advanced Parkinson’s disease. ND0611 is a proprietary carbidopa liquid formula administered sub-cutaneously via a dermal patch to increase the bioavailability and efficacy of orally- administered levodopa. Results of this study support the continued development of ND0611 for the treatment of Parkinson’s disease.

[Read More]